Business Description
Repligen Corp
NAICS : 339112
SIC : 3841
ISIN : US7599161095
Share Class Description:
RGEN: Ordinary SharesTotal Employee Number:
2,000Description
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.14 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.33 | |||||
Debt-to-EBITDA | 3.9 | |||||
Interest Coverage | 2.39 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 6.9 | |||||
Beneish M-Score | -2.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.2 | |||||
3-Year EBITDA Growth Rate | -12.8 | |||||
3-Year EPS without NRI Growth Rate | -19.5 | |||||
3-Year FCF Growth Rate | 34 | |||||
3-Year Book Growth Rate | 2.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 23.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 13.61 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 65.53 | |||||
9-Day RSI | 63.02 | |||||
14-Day RSI | 61.95 | |||||
3-1 Month Momentum % | 8.88 | |||||
6-1 Month Momentum % | -21.62 | |||||
12-1 Month Momentum % | -2.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.2 | |||||
Quick Ratio | 7.78 | |||||
Cash Ratio | 6.22 | |||||
Days Inventory | 166.28 | |||||
Days Sales Outstanding | 73.01 | |||||
Days Payable | 29.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.5 | |||||
Shareholder Yield % | 0.1 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 52.9 | |||||
Operating Margin % | 6.85 | |||||
Net Margin % | 6.73 | |||||
EBITDA Margin % | 23.1 | |||||
FCF Margin % | 13.68 | |||||
OCF Margin % | 17.12 | |||||
ROE % | 2.48 | |||||
ROA % | 1.77 | |||||
ROIC % | 2.26 | |||||
3-Year ROIIC % | -56.7 | |||||
ROC (Joel Greenblatt) % | 14.16 | |||||
ROCE % | 2.81 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 160.27 | |||||
Forward PE Ratio | 71.94 | |||||
PE Ratio without NRI | 80.13 | |||||
Shiller PE Ratio | 128.79 | |||||
Price-to-Owner-Earnings | 192.81 | |||||
PS Ratio | 10.71 | |||||
PB Ratio | 3.86 | |||||
Price-to-Tangible-Book | 12.9 | |||||
Price-to-Free-Cash-Flow | 78.1 | |||||
Price-to-Operating-Cash-Flow | 62.47 | |||||
EV-to-EBIT | 103 | |||||
EV-to-Forward-EBIT | 115.02 | |||||
EV-to-EBITDA | 45.59 | |||||
EV-to-Forward-EBITDA | 51.52 | |||||
EV-to-Revenue | 10.53 | |||||
EV-to-Forward-Revenue | 9.75 | |||||
EV-to-FCF | 76.96 | |||||
Price-to-GF-Value | 0.82 | |||||
Price-to-Projected-FCF | 3.3 | |||||
Price-to-Median-PS-Value | 0.8 | |||||
Price-to-Graham-Number | 6.78 | |||||
| Price-to-Net-Current-Asset-Value | 24.2 | |||||
Earnings Yield (Greenblatt) % | 0.97 | |||||
FCF Yield % | 1.28 | |||||
Forward Rate of Return (Yacktman) % | -9.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RGEN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Repligen Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 763.339 | ||
| EPS (TTM) ($) | 0.9 | ||
| Beta | 1.1692 | ||
| 3-Year Sharpe Ratio | 0.07 | ||
| 3-Year Sortino Ratio | 0.11 | ||
| Volatility % | 32.31 | ||
| 14-Day RSI | 61.95 | ||
| 14-Day ATR ($) | 6.253242 | ||
| 20-Day SMA ($) | 136.867 | ||
| 12-1 Month Momentum % | -2.42 | ||
| 52-Week Range ($) | 100.99 - 175.77 | ||
| Shares Outstanding (Mil) | 56.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Repligen Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Repligen Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-28 08:30 | In 110 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 | In 109 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 08:30 | In 19 days | ||
| Second quarter earnings results for 2026 | 2026-07-29 | In 18 days | ||
| William Blair 46th Annual Growth Stock Conference | 2026-06-03 10:40 | 121.13 (-0.54%) | ||
| General meeting for 2026 | 2026-05-14 08:00 | 107.03 (-5.84%) | ||
| Guidance call for 2026 | 2026-05-12 10:00 | 115.91 (-6.66%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 08:00 | 118.21 (+1.86%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 118.21 (+1.86%) | ||
| KBCM Virtual Healthcare Forum | 2026-03-18 14:15 | 119.27 (+1.82%) |
Show
Entries
Repligen Corp Frequently Asked Questions
What is Repligen Corp(RGEN)'s stock price today?
The current price of RGEN is $144.24. The 52 week high of RGEN is $175.77 and 52 week low is $100.99.
When is next earnings date of Repligen Corp(RGEN)?
The next earnings date of Repligen Corp(RGEN) is 2026-07-29 Est..
Does Repligen Corp(RGEN) pay dividends? If so, how much?
Repligen Corp(RGEN) does not pay dividend.
Guru Commentaries on NAS:RGEN
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen | 2020-12-08 |
Articles on Repligen Corp
Headlines
See More- 1
Jun 27, 2026
BioLife is said to have drawn takeover interest from Repligen
Seeking Alpha • 11:20am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers